Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Equity Income: 2015-2020

Historic Equity Income for Ligand Pharmaceuticals (LGND) over the last 5 years, with Mar 2020 value amounting to -$25.5 million.

  • Ligand Pharmaceuticals' Equity Income fell 247.20% to -$25.5 million in Q1 2020 from the same period last year, while for Mar 2020 it was -$39.9 million, marking a year-over-year decrease of 192.66%. This contributed to the annual value of $2.9 million for FY2019, which is 93.94% down from last year.
  • As of Q1 2020, Ligand Pharmaceuticals' Equity Income stood at -$25.5 million, which was down 400.19% from $8.5 million recorded in Q4 2019.
  • In the past 5 years, Ligand Pharmaceuticals' Equity Income ranged from a high of $59.9 million in Q3 2018 and a low of -$74.0 million during Q4 2018.
  • Its 3-year average for Equity Income is $2.8 million, with a median of $8.5 million in 2019.
  • The largest annual percentage gain for Ligand Pharmaceuticals' Equity Income in the last 5 years was 5,975.47% (2018), contrasted with its biggest fall of 1,758.18% (2018).
  • Quarterly analysis of 5 years shows Ligand Pharmaceuticals' Equity Income stood at -$9.0 million in 2016, then spiked by 149.64% to $4.5 million in 2017, then slumped by 1,758.18% to -$74.0 million in 2018, then skyrocketed by 111.46% to $8.5 million in 2019, then tumbled by 247.20% to -$25.5 million in 2020.
  • Its last three reported values are -$25.5 million in Q1 2020, $8.5 million for Q4 2019, and -$10.5 million during Q3 2019.